NCT04027387View on ClinicalTrials.gov

Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 14, 2019

Primary Completion Date

August 18, 2021

Study Completion Date

August 18, 2021

Conditions
HIV-1-infection
Interventions
BIOLOGICAL

TMB-365

An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection

Trial Locations (6)

32803

Orlando Immunology Center, Orlando

34982

Midway Immunology and Research Center, Ft. Pierce

39213

University of Mississippi Medical Center Division of Infectious Diseases, Jackson

75246

North Texas Infectious Disease Consultants, Dallas

94115

Quest Clinical Research, San Francisco

00909

Clinical Research PR, Inc, San Juan

Sponsors

Collaborators (1)

Westat
All Listed Sponsors
collaborator

Westat

OTHER

lead

TaiMed Biologics Inc.

INDUSTRY